shot-button
E-paper E-paper
Home > News > World News > Article > Pfizer Moderna jabs effective against variants found in India Study

Pfizer, Moderna jabs effective against variants found in India: Study

Updated on: 20 May,2021 07:49 AM IST  |  Washington
Agencies |

A study shows that the newly identified SARS-CoV-2 variants found in India are neutralised well by antibodies in individuals vaccinated with both vaccines

Pfizer, Moderna jabs effective against variants found in India: Study

A waitress holds customers’ orders at a restaurant terrace in the Strasbourg district of La Petite-France. Pic/AFP

Covid-19 vaccines developed by Pfizer and Moderna work against B.1.617 variant of the virus that was first identified in India, according to a new study.


The study shows that the newly identified SARS-CoV-2 variants identified in India are neutralised well by antibodies in individuals vaccinated with both vaccines.


“This finding predicts that even though the new variants are highly transmissible, vaccinated individuals will be protected from infection with the new variants,” senior author Professor Nathaniel R Landau told ANI on Tuesday.


The lab-based study, which was carried out by the NYU Grossman School of Medicine and NYU Langone Center, is considered preliminary.

Professor Landau and the team of researchers worked on blood samples from people who were vaccinated with Pfizer or Moderna vaccines.

The blood drawn was exposed in a lab to engineered pseudovirus particles that contained mutations in the “spike” region of the Coronavirus, which were particular to either the B.1.617 or B.1.618 variants, first found in India. And this mixture was exposed to lab-grown cells, to see how many would become infected. 

Researchers found an almost four-fold reduction in the amount of neutralising antibodies Y-shaped proteins the immune system creates to stop pathogens from invading cells.

“People should get vaccinated. It will protect them, their family members and will slow the emergence of new variants,” Landau asserted.

President Biden announced on Monday that he will export 20 million doses of vaccines from Pfizer In., Moderna Inc and Johnson & Johnson, on top of 60 million AstraZeneca doses he had already planned to give to other countries.

During a Tuesday White House briefing, Fauci said initial studies indicated the Pfizer-BioNTech and Moderna vaccines are “at least partially and probably quite protective” against serious illness, hospitalisation and death, “indicating another very strong reason why we should be getting vaccinated”.

Also Read: Mumbai’s daily Covid-19 cases rise above 1,000 again

US rights leader seeks 60 mn doses for India

Eminent American civil rights leader Rev. Jesse L. Jackson is urging President Joe Biden to release 60 million doses of Covid-19 vaccines to India, which is experiencing one of the worst outbreaks of the pandemic in the world. Rev. Jackson will be joined by a number of prominent Indian leaders in the national capital on Wednesday, to make a public appeal to Biden for more humanitarian aid, according to a community statement.

Hungary extends state of emergency

The Hungarian Parliament has again extended a state of emergency that allows the government to impose measures to stop the Covid-19 spread. The Parliament in Budapest voted on Tuesday to extend the state of emergency until the autumn.

5,46,512
No. of new cases reported globally in the past 24 hours

16,43,48,314
Total no. of cases worldwide

34,07,240
Total no. of deaths worldwide

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!


Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK